Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.873,81
-1,36%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Arbutus Biopharma Corporation (ABUS) Arbutus Biopharma Corporation (ABUS) Notizie

Arbutus Biopharma Corporation

ABUS
2,73
0,01 (0,37%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/4/202413:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202414:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:31EDGAR2Form 8-K - Current report
29/2/202413:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202413:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202422:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:31EDGAR2Form 8-K - Current report
08/1/202413:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04/1/202422:09EDGAR2Form 8-K - Current report
21/11/202314:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202322:02EDGAR2Form 8-K - Current report
08/11/202313:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07/11/202322:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:31EDGAR2Form 8-K - Current report
07/11/202313:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202313:16EDGAR2Form 8-K - Current report
07/11/202313:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202313:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202313:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202314:06EDGAR2Form 8-K - Current report
11/10/202314:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11/9/202323:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202322:16EDGAR2Form 8-K - Current report
11/9/202322:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202313:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03/8/202322:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202313:31EDGAR2Form 8-K - Current report
03/8/202313:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/7/202313:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
13/7/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202322:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202322:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202313:31EDGAR2Form 8-K - Current report
12/7/202313:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
10/7/202322:02EDGAR2Form 8-K - Current report
10/7/202322:01GLOBEArbutus Appoints Two New Executives
21/6/202313:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21/6/202308:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07/6/202308:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..
Apertura: 2,73 Min: 2,70 Max: 2,78
Chiusura: 2,72

La tua Cronologia

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network